ERBB2 and ovarian carcinoma: CD19 CAR T cells that secrete CD19-BP–targeting HER2 killed HER2-positive cells and CD19-positive cells (OR gate) and showed the comparable efficacy to HER2 CAR T cells in an ectopic HER2-positive ovarian cancer CDX model (47).